News for Milestone Pharmaceuticals Inc. (MIST)

**media[544484]**

Significant Stock Acquisition by RTW INVESTMENTS, LP (Trades, Portfolio) On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a notable stock

**media[526212]**

MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. ( MIST) (the ”œCompany” or ”œMilestone”), today announced

MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. ( MIST) today announced that President and CEO, Joe Oliveto, an

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Milestone Pharmaceuticals maintains Buy rating from TD Cowen

Milestone Pharmaceuticals (MIST) stock jumps as Rodman & Renshaw initiates coverage with a Buy rating, citing potential FDA nod for lead drug Cardamyst. Read more here.

Milestone Pharmaceuticals Inc. (MIST) Wednesday announced that the FDA has accepted the Company's New Drug Application or NDA for Cardamyst nasal spray to manage paroxysmal supraventricular tachycardia or PSVT.

Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pennsylvania-based healthcare business Societal CDMO, Inc. (SCTL) is up over 132% in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17.

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The S&P 500 also rose, gaining, 0.34% to 4,770.79.

Read Stock Analysts’ Updated EPS Estimates for April 21st (ADMA, AFLYY, AIKI, ASX, ATIP, AUGX, AVA, AVDX, BAM, BBAI) at ETF Daily News

GuruFocus Article or News written by GuruFocusNews and the topic is about:

GuruFocus Article or News written by GuruFocusNews and the topic is about: